glp-1 agonists and sglt2 inhibitors combination GLP1 Receptor vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Pioglitazone with SGLT2 inhibitors or

We actually see a 25% reduction in suicidal ideation, Al-Aly noted

Robert Kushner: We are really living in the GLP-1 generation now

Chen C, Zhou R, Fu F, Xiao J

Fiber Managing the Most Common GLP-1 Side Effect Why it matters: Constipation is the most persistent long-term GI side effect of GLP-1 medications

For semaglutide , a phase 2 trial published in the New England Journal of Medicine (2021) examined daily semaglutide 0.4 mg in NASH patients and found that 59% achieved NASH resolution compared to 17% with placebo

In the most recent GFAPS wave, nearly 20% of respondents said that they have not yet used the drugs, but they are considering using them this year